DFine Secures $30 Million in Series D Funding

This post was commissioned on October 29, 2008, and it was categorized as Venture Capital, funding.

Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.

DFine, developer of
minimally invasive solutions for treating vertebral compression fractures
(VCFs), has secured a $30 million round of investment in its Series D
funding led by BBT Fund LP and Highland Capital Management. Other investors
include Prospect Venture Partners and Vanguard Ventures.

DFine is dedicated to developing treatments for VCFs that relieve pain
and improve quality of life for patients. More than 700,000 new VCFs occur
every year in the United States due to osteoporosis, tumor growth and
traumatic injury, accounting for nearly 150,000 hospital admissions and
resulting in close to $1.6 billion in annual costs.(1)

Minimally invasive treatment of VCFs, percutaneous vertebral
augmentation (also known as vertebroplasty or kyphoplasty), require
placement of bone cement into the fractured vertebra. Percutaneous
vertebral augmentation offers many benefits compared to a conventional
surgical approach including reduced procedure time, shorter hospital stays,
shorter recovery period and the elimination of brace usage.

DFine Secures $30 Million in Series D Funding
-(Via PR Newswire: Pharmaceuticals/Biotechnology.)

Theoretically Related Posts

April 16, 2009 -- Lycera Closes $36 Million Series A (0)
January 16, 2009 -- Hydra Biosciences Raises $22 Million in Series D Financing (1)
October 29, 2008 -- Salient Surgical Technologies Nets A $17.9M Series F (0)
October 28, 2008 -- Lutonix Inc. Announces $20 Million Series B Financing (0)
August 12, 2008 -- Heathcare / Medical Venture Capital Groups (1)
April 15, 2009 -- Synageva Nets $30M (0)
November 17, 2008 -- Zafgen Raises $14 Million in Series B (0)
November 11, 2008 -- Accera Completes $35 Million Series C Financing (1)
November 1, 2008 -- Fidelity Biosciences Takes Over EnVivo Pharmaceuticals (1)
October 30, 2008 -- Alnara Pharmaceuticals, Inc. Secures $20 Million in Series A Round (0)

This post was constructed by

Eben Tessari

.

Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.

If one were so inclined, one could follow him at any of these fine web 2.0 establishments: